They also found that the transcription factor Homeobox C4 (HOXC4) is a clinical biomarker for aggressive PRAD and that abnormal upregulation of HOXC4 aggravates PRAD progression [45]. Here, HOXC4 is linked to prostate adenocarcinoma.